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There is good evidence that the Ras/MAPK signaling
pathway plays an important role in signaling via FGFActivation of the Ras/MAPK signaling cascade is es-
receptors (Bar-Sagi and Feramisco, 1985; Noda et al.,sential for growth factor±induced cell proliferation and
1985). It is now well established that the adaptor proteindifferentiation. In this report, we describe the purifica-
Grb2 (Clark et al., 1992; Lowenstein et al., 1992) linkstion, cloning, and characterization of a novel protein,
receptor tyrosine kinases with the Ras signaling path-designated FRS2, that is tyrosine phosphorylated and
way by binding to the guanine nucleotide-releasing fac-binds to Grb2/Sos in response to FGF or NGF stimula-
tor Sos through its SH3 domains and to tyrosine-phos-tion. We find that FRS2 is myristylated and that this
phorylated receptors via its SH2 domain (Schlessinger,modification is essential for membrane localization,
1994). However, Grb2 does not bind directly to FGFtyrosine phosphorylation, Grb2/Sos recruitment, and
receptors. This raises the possibility that additional cel-MAPK activation. FRS2 functions as a lipid-anchored
lular proteins become tyrosine-phosphorylated and binddocking protein that targets signaling molecules to
to Grb2 in response to FGF stimulation and thus may linkthe plasma membrane in response to FGF stimulation
FGF receptors with the Ras/MAPK signaling pathway. Into link receptor activation with the MAPK and other
this report, we demonstrate that FGF stimulationsignaling pathways essential for cell growth and differ-
induces tyrosine phosphorylation of a novel lipid-entiation. Finally, we demonstrate that FRS2 is closely
anchored docking protein, termed FRS2, that forms arelated and probably indentical to SNT, the long-
complex with Grb2/Sos, thus linking FGF-receptor acti-sought target of FGF and NGF receptors.
vation to the Ras/MAPK signaling pathway.
Introduction
Results
The family of fibroblast growth factors (FGFs) consist of
at least ten different growth factors that control cellular We searched for tyrosine-phosphorylated proteins that
bind to Grb2 in response to FGF stimulation. Immuno-processes such as growth, differentiation, and cell mi-
gration (reviewed in Basilico and Moscatelli, 1992). FGFs precipitation of Grb2 from lysates of aFGF (acidic FGF)
-stimulated cells, followed by SDS±PAGE and immu-induce their biological responses by binding to and acti-
vating a family of cell-surface receptors with intrinsic noblotting with anti-phosphotyrosine (pY) antibodies,
showed that aFGF induces association of Grb2 withprotein tyrosine kinase activity, termed FGF receptors
(reviewed in Jaye et al., 1992). Dimerization of FGF re- several pY-containing proteins (Figure 1A) but not with
the activated FGF receptor (Figure 1B). Three of theceptors is essential for kinase activation and for receptor
autophosphorylation, and requires the concerted action Grb2-associated proteins (p46, p52, and p68) are the
known Shc isoforms and are recognized by anti-Shcof FGF together with soluble or cell-surface heparan
sulfate proteoglycans (reviewed in Schlessinger et al., antibodies (data not shown). A fourth prominent species
migrates in SDS±PAGE as a doublet of 92±95 kDa (Figure1995).
Upon activation, receptor tyrosine kinases undergo 1A). This doublet was detected in Grb2 immunoprecipi-
tates from lysates of three different cell lines (NIH-3T3,rapid autophosphorylation on numerous tyrosine resi-
dues. Autophosphorylation sites located within the cata- L6 myoblasts, and PC12 cells) that were stimulated with
aFGF but could not be detected when these cells werelytic domain are crucial for stimulation of kinase activity,
while autophosphorylation sites located in other regions treated with epidermal growth factor (EGF) (Figure 1A).
Rather, in EGF-treated cells, only tyrosine-phosphory-are usually involved in the recruitment of cellular target
proteins (Pawson and Schlessinger, 1993). FGFR1 (Flg) lated Shc and EGF receptor (EGFR) could be seen to
associate with Grb2 (Figures 1A and 1B; Batzer et al.,contains at least seven autophosphorylation sites. Two
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Figure 1. aFGF Induces Tyrosine Phosphor-
ylation of FRS2 and Association with Grb2
(A and B) PC12, L6 myoblasts, or NIH-3T3
cells were stimulated with aFGF or EGF,
lysed, and immunoprecipitated with anti-
Grb2 antibodies. Samples were analyzed by
immunoblotting with anti-pY antibodies (A),
anti-FGFR1 antibodies (B, left), or anti-EGFR
antibodies (B, right).
(C) PC12 cells were stimulated with aFGF,
lysed, and the samples were precipitated with
a GST-fusion protein containing the SH2 of
Grb2 or point mutant SH2 (R86K) domain.
Samples were separated by SDS±PAGE and
immunoblotted with anti-pY antibodies.
(D) Coprecipitation of FRS2 with Grb2 and
Sos1. FGF-stimulated or nonstimulated PC12
cells were lysed and subjected to immuno-
precipition with anti-FGFR1, anti-Grb2, or
anti-Sos1. The samples were analyzed by
SDS±PAGE and, after transfer to nitrocellu-
lose filter, immunoblotted with anti-pY anti-
bodies.
(E) Direct binding of Grb2 to FRS2 in FGF-
stimulated cells. Lysates from aFGF-stimu-
lated or unstimulated PC12 cells were sub-
jected to immunoprecipitation with anti-Grb2,
anti-Sos1, or anti-FGFR1 antibodies. After
SDS±PAGE, the samples were transfered to
nitrocellulose filter and blotted with GST-
Grb2.
1994). Thus, while EGFR can recruit Grb2 directly, FGFR Both GST-Grb2 and the form with the mutated SH3 do-
main could bind directly to tyrosine-phosphorylatedappears todo so only indirectly (Figure 1B) via intermedi-
ate proteins such as Shc and p92±95. We call the newly FRS2 (data not shown), providing further confirmation
of a direct interaction involving the Grb2±SH2 domain.identified p92±95 protein FGF Receptor Substrate 2
(FRS2). The three different cell lines in which we detect
FGF-stimulated association of FRS2 with Grb2 respond Grb2±FRS2 Complex Is Bound to Sos1
in FGF-Stimulated Cellsdifferently to aFGFÐwhile NIH-3T3 cells and L6 my-
oblasts proliferate, PC12 cells are induced to differenti- Grb2 binds to the guanine nucleotide-releasing factor
Sos1 through its two SH3 domains (Schlessinger, 1994).ate. The observation that FRS2 is involved in each case
suggests that it is a key intermediate in FGF-receptor We therefore examined whether the complex formed
between FRS2 and Grb2 also interacts with Sos1. Ly-signaling, in spite of the different biological outcome of
aFGF stimulation of these cells. sates of aFGF-stimulated or unstimulated cells were
immunoprecipitated with antibodies against FGFR1,
Grb2, or Sos1. The immunoprecipitates were separatedThe SH2 Domain of Grb2 Binds to FRS2
Grb2 contains one SH2 domain flanked by two SH3 by SDS±PAGE and immunoblotted with anti-pY antibod-
ies (Figure 1D). Tyrosine-phosphorylated FRS2 wasdomains (Lowenstein et al., 1992). Since tyrosine-phos-
phorylated FRS2 binds to Grb2, we examined its ability seen to be associated with both Grb2 and Sos1 in aFGF-
stimulated cells but was not detected in anti-FGFR1 (orto interact with the SH2 domain alone. A GST-fusion
protein of the Grb2±SH2 domain was used to precipitate anti-Shc) immunoprecipitates. This experiment demon-
strates that a ternary complex, composed of Grb2, Sos1,associating proteins from lysates of FGF-stimulated
cells. Analysis with anti-pY antibodies (Figure 1C) and FRS2 is formed in response to aFGF stimulation.
Far Western blotting experiments also confirmed theshowed that both tyrosine-phosphorylated Shc and
FRS2 were associated with the Grb2±SH2 domain in existenceof a complex containingFRS2, Grb2, and Sos1
(Figure 1E). We therefore conclude that association be-an FGF-dependent manner. By contrast, a GST-fusion
protein with a mutated binding-defective form of the tween Grb2 and FRS2 is mediated by the SH2 domain
of Grb2 and is dependent upon aFGF stimulation, whileGrb2±SH2 (R86K) failed to precipitate either protein. To
determine whether the interaction between FRS2 and the association between Sos1 and Grb2 is constitutive
and mediated by the SH3 domains.the SH2 domain of Grb2 is direct, we applied the far
Western technique. Lysates from aFGF-stimulated or
unstimulated cells were immunoprecipitated with anti- Purification of FRS2
FRS2 was purified from lysates of aFGF-stimulated NIH-Grb2 antibodies and analyzed by blotting with GST (as
a control), GST-Grb2, or GST-Grb2 (P49L), a point mu- 3T3 cells by using an affinity matrix containing immobi-
lized Grb2±SH2 domain. The tyrosine-phosphorylatedtant in the N-terminal SH3 domain corresponding to the
Sem-5 loss-of-function allele (Lowenstein et al., 1992). bound FRS2 was released from the SH2-Affigel matrix
Lipid-Anchored Docking Protein
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Figure 2. Purification, cDNA Cloning, Amino
Acid Sequence, and Expression of FRS2
(A) An aliquot of affinity-purified FRS2 was
separated by SDS±PAGE, transfered to nitro-
cellulose filter, and stained with Ponceau S
(inset). The band corresponding to FRS2 was
excised from the gel, digested with trypsin,
and analyzed by reverse-phase HPLC. Four
peptides (peptides #1, #2, #3, and #4) were
purified, and their amino acid sequence de-
termined.
(B) Deduced amino acid sequence of FRS2.
Locations of four trypic peptides from FRS2
are underlined. The myristylation site is
underlined by a broken line. Putative Grb2
binding sites are in bold letters. The PTB do-
main is boxed.
(C) Comparison of the sequence of the PTB
domain of FRS2 (amino acids 11±139) with the
PTB domain of murine IRS1 (BESTFIT, GCG
sequence analysis software). The compari-
son shows 29% identity and 50% similarity.
(D) Immunoprecipitation of endogenous
FRS2 from NIH-3T3 cells with anti-FRS2 anti-
bodies. NIH-3T3 cells were stimulated with
aFGF. Cell lysates were immunoprecipitated
with anti-Grb2, anti-FRS2, anti-Sos1, anti-
Shc, and anti-FGFR1 antibodies and ana-
lyzed by immunoblotting with anti-FRS2, anti-
Grb2, anti-FGFR1, and anti-pY antibodies.
(E) Tyrosine phosphorylation of FRS2 in response to different growth factors. PC12 cells were stimulated with NGF, EGF, aFGF, or insulin,
and NIH-3T3 cells were stimulated with PDGF, aFGF, or insulin for 5 min at 378C. The cells were lysed and subjected to immunoprecipitation
with anti-FRS2 antibodies, SDS±PAGE, and immunoblotting with anti-pY antibodies.
by boiling in the presence of SDS and reducing agents. sequence (MGXXXS/T) at the amino-terminus of the
molecule MGSCCS (Resh, 1994). In addition, FRS2 con-The FRS2-containing sample was then subjected to a
second affinity-chromatography purification step using tains a stretch of 120 amino acids (residues 11±139) with
29% sequence identity to the phosphotyrosine bindinganti-pY antibodies. FRS2 protein was released from the
column using phenylphosphate and analyzed by SDS± (PTB) domain of IRS1 (Figure 2C) (O'Neill et al., 1994).
FRS2 also contains four potential Grb2 binding sites atPAGE (Figure 2A, inset). The purified FRS2 protein band
was digested with trypsin, and the tryptic peptides were tyr-196, tyr-306, tyr-349, and tyr-392 (Figure 2B).
Northern blot analysis of mRNA isolated from adultresolved by reverse-phase HPLC. The amino acid se-
quences of four tryptic peptides were determined using mouse tissues demonstrated that FRS2 is ubiquitously
expressed and is most abundant in brain, kidney, lung,a solid-phase microsequencer (Figure 2A).
ovary, and testis (data not shown). To characterize
the FRS2 protein, we raised polyclonal antibodies incDNA Cloning of FRS2
Peptide sequences from FRS2 were used to design oli- rabbits against a C-terminal portion of FRS2 expressed
in E. coli as a GST-fusion protein. The anti-FRS2 anti-gonucleotides for amplification by PCR of cDNA pre-
pared from mRNA isolated from NIH-3T3 cells. A 1.2 kb bodies precipitated a protein from NIH-3T3 cells or from
PC12 cells that migrates in SDS±PAGE as a doublet ofPCR product contained the sequences of proteolytic
peptide #1 (FVLGPTPVQK) and peptide #2 (XVYENINGL 92±95 kDa.
We next examined the association between Grb2 andSIPSASGV) from FRS2. The 1.2 kb PCR product was
then used as a probe for screening a cDNA library from FRS2 in lysates from NIH-3T3 cells using anti-FRS2
antibodies. NIH-3T3 cells were stimulated with aFGF,Swiss 3T3 cells. Two overlapping clones, lp90±1 and
lp90±2, were isolated. Determination of the nucleotide and lysates prepared from unstimulated or stimulated
cells were then subjected to immunoprecipitation withsequences of the two clones demonstrated that lp90±2
contained the sequences of all four tryptic peptides iso- antibodies against Grb2, FRS2, Sos1, Shc, or FGFR1,
followed by immunoblotting with several different anti-lated from FRS2 and that lp90±2 represents a full-length
cDNA clone of FRS2. bodies (Figure 2D). This experiment showed ligand-
dependent association of Grb2 with tyrosine-phosphor-The deduced amino acid sequence of FRS2 is pre-
sented in Figure 2B. The coding sequence of FRS2 be- ylated FRS2 in aFGF-stimulated cells. Similarly, Sos1
was found to be associated with FRS2 only in aFGF-gins at nt 308. The first methionine is within a Kozak
consensus sequence and is followed by an open reading stimulated cells. We could not detect association be-
tween FRS2 and FGFR1 or between FRS2 and Shc inframe (ORF) of 1527 bp, ending with a stop codon at nt
1834. This ORF encodes a protein containing 508 amino FGF-stimulated or unstimulated cells. Similarly, we were
unable to detect the association between FRS2 and theacids with a predicted molecular mass of 56.8 kDa. The
sequence of FRS2 contains a consensus myristylation signaling molecules Nck, phospholipase C-g, or p85,
Cell
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Figure 3. Membrane Localization of FRS2
and Close Similarity to SNT
(A) FRS2 is myristylated. 293 cells were
transfected with wild type or G2A point mu-
tant expression vectors, labeled with [3H]myr-
istic acid, lysed, and immunoprecipitated
with anti-FRS2 antibodies. Samples were re-
solved by SDS±PAGE and visualized by anti-
FRS2 immunoblotting (upper) and autoradi-
ography (lower).
(B) Immunofluorescent localization of FRS2.
HeLa cells were transiently transfected with
expression vectors that direct the synthesis
of wild-type FRS2 or the G2A point mutant.
After 24 hr, the cells were fixed, permeabil-
ized, and labeled with affinity-purified anti-
FRS2 antibodies followed by staining with
Texas red-conjugated goat anti-rabbit anti-
bodies. The same protocol was used for
staining of NIH-3T3 cells. The cells were ex-
amined by fluorescence microscopy. (a and
b) Staining of wild-type FRS2 expressed
in HeLa cells. (c) Staining of endogenous FRS2 in NIH-3T3 cells. (d) Staining of G2A mutant expressed in HeLa cells.
(C) Subcellular fractionation of NIH-3T3 cells. Parental NIH-3T3 or cells transfected with the G2A mutant were left untreated (2) or stimulated
with aFGF (1) for 5 min at 378C. Soluble and particulate fractions were prepared and immunoprecipitated with anti-FGFR1 or anti-FRS2
antibodies. Samples were analyzed by immunoblotting with anti-FGFR1, anti-FRS2, anti-Grb2, and anti-pY antibodies.
(D) FRS2 is closely related and probably identical to SNT. PC12 cells were stimulated with aFGF or NGF. Lysates from aFGF-stimulated or
unstimulated cells were subjected to immunoprecipitation with anti-Grb2, anti-FRS2, or were incubated with agarose beads p13suc1. The
samples were analyzed by SDS±PAGE and immunoblotted with anti-FRS2 or anti-pY antibodies.
the regulatory subunit of PI-3 kinase (data not shown). were permeabilized, labeled with anti-FRS2 antibodies,
and analyzed by fluorescence microscopy. This experi-Taken together, these experiments demonstrate that
aFGF stimulation leads to tyrosine phosphorylation of ment demonstrates that wild-type FRS2 is targeted to
the cell membrane and that myristylation is required forFRS2, which in turn binds to Grb2/Sos1, forming an
FGF-dependent ternary complex. this localization.
We also used a cellular fractionation procedure toWe have also examined the status of FRS2 phosphor-
ylation in response to several different growth factors. study the distribution of wild-type FRS2 and the G2A
The experiment presented in Figure 2E shows that aFGF mutant. Particulate and soluble fractions were prepared
or NGF stimulated tyrosine phosphorylation of FRS2, from untreated or aFGF-treated NIH-3T3 cells, and FRS2
while PDGF, EGF, or insulin did not induce tyrosine was immunoprecipitated from both cellular fractions
phosphorylation of FRS2. (Figure 3C). Endogenous FRS2 was found to be associ-
ated exclusively with the particulate fraction, and aFGF
FRS2 Is Myristylated and Targeted stimulation led to tyrosine phosphorylation of FRS2 and
to the Cell Membrane binding to Grb2. By contrast, the nonmyristylated mu-
We examined the role of the putative myristylation se- tant (G2A) of FRS2 was found in the soluble fraction and
quence of FRS2 by generation of a point mutant (G2A) was not tyrosine phosphorylated in aFGF-stimulated
in which a key glycine residue in the consensus se- cells. Together, our studies show that FRS2 is myristy-
quence was replaced by alanine. Expression vectors lated and that myristylation is essential for its targeting
that direct the synthesis of wild-type FRS2 or the G2A to the cell membrane, for tyrosine phosphorylation of
mutant were transiently expressed in human 293 cells. FRS2, and for recruitment of Grb2.
The transfected cells were labeled with [3H]myristic acid,
lysed, subjected to immunoprecipitation with anti-FRS2
FRS2 Is Closely Related to SNTantibodies, and analyzed by 8% SDS±PAGE and autora-
We have examined the possibility whether FRS2 is re-diography. As shown in Figure 3A, incorporation of
lated to suc1-associated neurotrophic factor target[3H]myristic acid could be detected in wild-type FRS2
(SNT) (Rabin et al., 1993). SNT was identified as a proteinbut not in the G2A point mutant.
of apparent molecularmass of 78±90 kDa that is tyrosineWe next analyzed the cellular distribution of FRS2 in
phosphorylated in response to NGF or FGF stimulationtransfected cells. HeLa cells were transiently trans-
in PC12 cells and can bind to p13suc1 immobilized onfected with an expression vector that directs the synthe-
agarose. Lysates from PC12 cells that were stimulatedsis of wild-type FRS2 or the G2A mutant. The cells were
with aFGF or NGF were subjected to immunoprecipita-permeabilized and labeled with affinity-purified anti-
tion with anti-FRS2 antibodies, anti-Grb2 antibodies, orFRS2 antibodies followed by staining with Texas red-
to p13suc1 immobilized on agarose as an affinity reagent.conjugated goat anti-rabbit antibodies. Visualization by
The samples were analyzed by SDS±PAGE and thenfluorescence microscopy demonstrated that, while wild-
immunoblotted with anti-FRS2 or anti-pY antibodies.type FRS2 is primarily associated with the cell mem-
The experiment presented in Figure 3D shows that anti-brane, the G2A mutant is distributed all over the cyto-
FRS2 antibodies and p13suc1 agarose beads recognizeplasm (Figure 3B). Figure 3B also shows membrane
localization of endogenous FRS2 in NIH-3T3 cells that the same tyrosine-phosphorylated Grb2-associated
Lipid-Anchored Docking Protein
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Figure 4. Enhancement of MAPK Activation by Overexpression of
FRS2
(A) 293 cells were transiently transfected with increasing amounts
of FRS2 expression vector (0.25 mg, lane 3; 0.5 mg, lane 4; 1 mg,
lane 5; 2 mg, lane 6; 2.5 mg, lane 7) and a constant amount of
Figure 5. Enhancement of MAPK Activation by Overexpression ofFGFR1 (1.5 mg, lanes 2±7) and HA-tagged ERK1 (1.5 mg, lanes 1±7)
FRS2 Is Dependent upon Rasexpression plasmids. Empty expression vector was used to adjust
the amount of transfected DNA to 10 mg. After 48 hr, the cells were 293 cells were cotransfected with expression vectors for FRS2 (2
lysed, and the expression of transfected proteins was determined mg, lanes 3 and 4), FGFR1 (1.5 mg, lanes 2±4), and HA-tagged ERK1
by immunoblotting with specific antibodies. (1.5 mg, lanes 1±4) in the absence or presence of Ras(N17) (10 mg,
(B) Activation of ERK1 by overexpression of FRS2. ERK1 enzymatic lane 4) expression vector. ERK1 enzymatic activity was determined
activity was determined as previously described using myelin basic as described in Figure 4B.
protein (MBP) as a substrate (Dikic et al., 1996). Quantitation was
carried out using a phosphoimager.
such a response (Figures 4C and 4D). FGF-induced(C) Reduced activation of MAPK in cells overexpressing the G2A
mutant. 293 Cells were transiently transfected with expression vec- MAPK activation enhanced by overexpression of the
tors for FGFR1 alone (1.5 mg, lane 2), FRS2 alone (1.5 mg, lane 3), nonmyristylated mutant was reduced by nearly 70% as
G2A mutant alone (2 mg, lane 4), or were cotransfected with FGFR1 compared to activation of MAPK induced by overex-
and wild-type FRS2 (lane 5) or FGFR1 and the G2A mutant (lane 6)
pression of wild-type FRS2 after subtractionof theback-together. All the samples were cotransfected with HA-tagged ERK1
ground activation induced by endogenous FRS2 mole-(1.5 mg, lanes 1±6). After 48 hr, cells were lysed, and the expression
cules that areexpressed in these cells (Figure 4D). Unlikeof proteins was determined by immunoblotting with specific anti-
bodies. wild-type FRS2, which is tyrosine phosphorylated and
(D) ERK1 enzymatic activity of each sample was determined as hence bound to Grb2, the nonmyristylated FRS2 mutant
described in (B). was not tyrosine phosphorylated in response to FGFR
activation (Figure 4C).
To examine the role of Ras in this process, we ana-species. We conclude that FRS2 is closely related and
probably identical to SNT, the long-sought target of FGF lyzed the effect of FRS2 overexpression on MAPK activ-
ity in the presence of a dominant interfering mutant ofand NGF receptors.
Ras (Ras[N17]). This experimentshowed that expression
of the dominant interfering mutant of Ras efficientlyEnhancement of MAPK Activation
by Overexpression of FRS2 blocked FRS2-enhanced MAPK activation (Figure 5).
However, the tyrosine phosphorylation of FRS2 and itsThe ability of FRS2 to recruit Grb2 to the cell membrane
in response to aFGF stimulation raised the possibility association with Grb2 were not affected by the expres-
sion of the dominant interfering Ras(N17) mutant. Thesethat its physiological role is to link FGF-receptor activa-
tion to the Ras/MAPK signaling pathway. We have ex- experiments therefore demonstrate that FRS2 functions
as a link between activated FGF receptors and the Ras/plored this possibility by transiently overexpressing in-
creasing amounts of FRS2, together with expression of MAPK cascade, and that FRS2 acts upstream of Ras in
this pathway.a constant amount of FGFR1 and an HA-tagged ERK1,
in 293 cells. The activity of ERK1 was measured in an
immunocomplex assay (Dikic et al., 1996) using myelin Overexpression of FRS2 Enhances FGF-Induced
Neurite Outgrowth in PC12 Cellsbasic protein (MBP) as a substrate. The experiments
presented in Figures 4A and 4B show that overexpres- PC12 cells were stably transfected with expression vec-
tors that direct the synthesis of either wild-type FRS2sion of FRS2 leads to a proportional increase in tyrosine
phosphorylation of MAPK and phosphorylation of MBP. or the nonmyristylated G2A mutant (Figure 6). The cells
were incubated with a low concentration of aFGF andWhile overexpression of wild-type FRS2 led to strong
stimulation of FGF-induced MAPK activation, overex- heparin that induced weak, barely detectable neurite
outgrowth in the parental PC12 cells (Figure 6B). Thepression of the nonmyristylated mutant did not induce
Cell
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experiment presented in Figure 6 demonstrates that putative Grb2 binding site in the presence of three mu-
tated tyrosine residues. The experiment presented inoverexpression of FRS2 leads to strong potentiation of
aFGF-induced neurite outgrowth in these PC12 cells. Figure 7B demonstrates that wild type as well as all five
FRS2 mutants were tyrosine phosphorylated in re-By contrast, expression of the nonmyristylated FRS2
mutant did not influence aFGF-induced neurite out- sponse to aFGF-stimulation of transfected 293 cells.
Each of the four FRS2 mutants (3F-196Y, 3F-306Y, 3F-growth in the transfected cells. The PC12 cell line used
in this study expresses endogenous FRS2 and low levels 349Y, and 3F-392Y) retained Grb2 binding, while the
association between Grb2 and 4F-mutant was signifi-of endogenous FGF receptors. Therefore, aFGF stimula-
tion promotes the flattening and adhesion of control cantly reduced but not eliminated, suggesting that Grb2
may also bind to FRS2 by an indirect mechanism.cells, and also induces weak neurite outgrowth of these
cells (Figure 6B). Immunoprecipition and immunoblot- We next examined the capacity of 4F-mutant to en-
hance aFGF-induced MAPK activation in 293 cells. Theting experiments confirmed that endogenous and
transfected wild-type FRS2 are both tyrosine phosphor- experiment presented in Figure 7C shows that the en-
hancement of MAPK activation by 4F-mutant was re-ylated, while the nonmyristylated FRS2 mutant is not
tyrosine phosphorylated in response to aFGF stimula- duced but not eliminated, as compared to the enhance-
ment of MAPK activity obtained by overexpression oftion (Figure 6A).
The role of Ras in FRS2-induced neurite outgrowth wild-type FRS2 in these cells. After subtraction of the
background activation of MAPK (probably owing towas tested by conditional expression inPC12 cellsof the
dexamethasone-inducible dominant interfering mutant tyrosine phosphorylation of endogenous FRS2 and Shc),
the 4F-mutant induced approximately 60% of the en-Ras(N17). Overexpression of Ras(N17) affected neither
the expression nor tyrosine phosphorylation of FRS2 hancement of MAPK induced by aFGF in cells over-
expressing wild-type FRS2. The partial activity of 4F-(Figure 6C). However, FRS2-induced neurite outgrowth
was totally blocked by overexpression of Ras(N17), mutant suggested that in addition to direct recruitment
of Grb2, FRS2 may also recruit Grb2 indirectly via anindicating that it is dependent upon Ras activation (Fig-
ure 6D). intermediate protein. Indeed, we have recently demon-
strated that aFGF stimulation leads to tyrosine phos-
phorylation of the protein tyrosine phosphatase Shp2Inhibition of FGF-Induced DNA Synthesis by
Microinjection of Anti-FRS2 Antibodies and to formation of a ternary complex composed of
FRS2, Shp2, and Grb2 (Y. R. H. et al., unpublished data).Rat embryo fibroblasts grown on gridded coverslips
were microinjected with a solution containing affinity- FRS2 is therefore able to recruit Grb2 directly and indi-
rectly via tyrosine phosphorylation and complex forma-purified FRS2 antibodies or, as a control, with preim-
mune antibodies. One hour after injection, the cells were tion with Shp2.
treated with 5 nM aFGF and 5 mg/ml heparin. BrdU was
added to the culture medium, and after 26 hr the cells
Discussionwere fixed, permeabilized, and stained with anti-BrdU
antibodies followed by rhodamine-labeled goat anti-
Stimulation of cell proliferation and differentiation bymouse antibodies. As shown in Figure 6E,aFGF-induced
FGF receptors depends on the Ras/MAPK signalingDNA synthesis was inhibited by more than 65% in cells
pathway (Bar-Sagi and Feramisco, 1985: Noda, et al.,microinjected with anti-FRS2 antibodies but not in cells
1985). The small adaptor protein Grb2 plays an impor-microinjected with control preimmune antibodies. This
tant role in linking receptor tyrosine kinase activation tofinding demonstrates that FRS2 is essential for FGF-
the Ras/MAPK signaling pathway (Schlessinger, 1994).induced DNA synthesis.
Unlike the EGF receptor and other receptors that bind
to Grb2 directly, FGF receptors do not bind directly toEffect of FRS2 Mutants on Enhancement
Grb2 upon FGF stimulation. It therefore appears thatof MAPK Activation
the activated FGFreceptors utilize an alternative indirectWe have generated various mutants of FRS2 and exam-
mechanism for activation of the Ras/MAPK signalingined their ability to enhance FGF-induced MAPK activa-
pathway. This mechanism probably involves intermedi-tion by transient-expression experiments in 293 cells.
ate proteins that recruit Grb2/Sos to the cell surface.The experiment presented in Figure 7A demonstrates
In this report, we describe the purification and cDNAthat overexpression of wild-type FRS2 enhances aFGF-
cloning of a likely intermediate in this process, i.e., FRS2.induced MAPK activation in 293 cells, while overexpres-
FRS2 contains both a consensus myristylation se-sion of a deletion mutant composed of the myristylation
quence and a putative PTB domain in its amino-termi-signal and the PTB domain but lacking most of the
nus, which are likely to be involved in its recruitment toC-terminal region of FRS2 did not enhance aFGF-
the cell membrane. FRS2 becomes tyrosine phosphory-induced MAPK activation in these cells. This experiment
lated upon activation of cells with aFGF and associatesdemonstrated that the C-terminal portion of FRS2 is
with the Grb2/Sos complex (via the Grb2±SH2 domain)essential for enhancement of MAPK activity.
in an aFGF-dependent manner. FRS2 is also tyrosineWe have used site-directed mutagenesis to generate
phosphorylated in response to NGF stimulation but notan FRS2 mutant that contains phenylalanine residues
in response to EGF, PDGF, or insulin stimulation. Experi-in place of the four putative Grb2 binding sites at Y196,
ments are presented demonstrating that FRS2 functionsY306, Y349, and Y392 (4F-mutant). Four additional mu-
as a novel lipid-anchored dockingprotein that links FGF-tants of FRS2 were generated (3F-196Y, 3F-306Y, 3F-
349Y, 3F-392Y mutants), each containing a single intact receptor activation to the Ras/MAPK signaling pathway
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Figure 6. Overexpression of FRS2 in PC12
Cells Enhances aFGF-Induced Neurite Out-
growth in a Ras-Dependent Manner
(A) Control PC12 cells and cells expressing
either wild-type FRS2 or the G2A mutant were
stimulated with aFGF. Cells were lysed, im-
munoprecipitated with anti-FRS2 antibodies,
and immunoblotted with either anti-FRS2 or
anti-pY antibodies. Bottom: quantitation of
neurite outgrowth was performed as de-
scribed in Experimental Procedures.
(B) Control PC12 cells orcells overexpressing
wild type or the G2A mutant were grownover-
night in complete growth medium (2) or in
medium containing aFGF and heparin. Neu-
rite outgrowth was scored and quantitated
following induction for 48 hr. Similar results
were obtained in four different experiments.
(C) PC12 cells, transfected with Ras(N17) un-
der the control of an inducible promotor were
left untreated (2) or treated with dexametha-
sone overnight. Cells were stimulated with
aFGF and heparin for 5 min at 378C, lysed,
immunoprecipitated with anti-FRS2 antibod-
ies, and immunoblotted with either anti-FRS2
or anti-pY antibodies. Total cell lysates were
immunoblotted with anti-Ras antibodies.
Bottom: quantitation of neurite outgrowth
was performed as described in Experimental
Procedures.
(D) PC12 cells expressing Ras(N17) were
grown overnight in complete growth medium
(2) or in medium supplemented with dexa-
methasone (Dex1), aFGF, and heparin, or
both. Neurite outgrowth was scored and
quantitated after 48 hr. Similar results were
obtained in two different experiments.
(E) Inhibition of FGF-induced DNA synthesis
by microinjection of anti-FRS2 antibodies.
Rat embryo fibroblasts grown on gridded
coverslips were microinjected with solution
containing affinity-purified anti-FRS2 antibodies or control antibodies. One hour after injection, the cells were treated with aFGF together with
heparin, and BrdU was added for 26 hr at 378C. The cells were fixed, permeabilized, labeled with anti-BrdU antibodies, and stained with
rhodamine-conjugated goat anti-mouse antibodies. Bars represent the percentage of BrdU-positive cells in injected areas.
and thus relays information from the cell surface to the the PTB domain of FRS2. The PTB domain was first
identified in the adaptor protein Shc (Blaikie et al., 1994;nucleus in response to FGF stimulation. A distinct pro-
tein designated p85/p90 or 80K-H, which is also tyrosine Kavanaugh and Williams, 1994) as a protein module that
binds to tyrosine-phosphorylated NPXYp sequences inphosphorylated in response to FGF stimulation and ap-
pears to bind to Grb2 but bears no similarity to FRS2, growth-factor receptors such as the EGF or NGF recep-
tors, as well as in other tyrosine-phosphorylated pro-was recently described (Goh et al., 1996). However, we
demonstrated that FRS2 is closely related to and proba- teins (Gustafson et al., 1995). IRS1 also contains a PTB
domain in its amino-terminus. The isolated PTB domainbly identical to SNT, the long-sought target of FGF and
NGF receptors (Rabin et al., 1993). from IRS1 binds to a tyrosine-phosphorylated NPXYp
sequence in the juxtamembrane domain of the insulinAs mentioned above, myristylation of FRS2 is essen-
tial for its targeting to the plasma membrane. Usually, receptor (O'Neill et al., 1994). Furthermore, the presence
of the PTB domain together with a neighboring PH do-protein myristylation alone is insufficient for stable mem-
brane association, and an additional targeting signal main is important for efficient tyrosine phosphorylation
of IRS1 in response to insulin stimulation (Gustafson etis necessary to generate a stable anchor to the cell
membrane (Resh, 1994). For example, several N-termi- al., 1995). Structural studies have shown that despite
poor sequence similarity between PTB domains andnally myristylated proteins, including the protein tyro-
sine kinases Fyn and Lck, achieve stable membrane PH domains, both protein modules exhibit the same
structural fold (reviewed in Lemmon et al., 1996). Theassociation with a secondanchor resulting from palmity-
lation of a Cys residue at position 3 (Milligan et al., 1995). emerging picture is that the biological function of
PH/PTB domains is to recruit their host proteins to theFRS2 contains Cys residues at positions 4 and 5, and
we were unable to detect its palmitylation in vivo. cell membrane in the vicinity of their physiological targets
(Lemmon et al., 1996). It is noteworthy that FGFR1, -2,The second targeting signal required to stabilize the
association of FRS2 with the cell membrane could be -3, and -4 do not contain NPXYp sequence motifs. The
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Figure 7. The C-terminal Portion of FRS2 Is
Required for Enhanced Activation of MAPK
(A) Human 293 cells were transfected with
expression vector that directs the synthesis
of FRS2 (2 mg, lane 3) or a deletion mutant
that encodes for the myristylation signal and
the PTB domain of FRS2 (1 mg, lane 4), to-
gether with FGFR1 expression vector (1.5 mg,
lanes 2±4) and HA-tagged ERK1 expression
vector (1.5 mg, lanes 1±4). After 48 hr, the cells
were lysed, and the expression of transfected
protein was determined by immunoblotting
with specific antibodies. ERK1 enzymatic
activity was determined as described in Fig-
ure 4B.
(B) FRS2 contains four Grb2 binding sites.
Human 293 cells were transfected with 2 mg
of FRS2 expression vector (lane 2), 4F-mutant
(lane 3), 3F-196Y mutant (lane 4), 3F-306Y
mutant (lane 5), 3F-349Y mutant (lane 6), and
3F-392Y mutant (lane 7) expression vectors,
together with FGFR1 expression vector (1 mg,
lanes 1±7). After 48 hr, the cells were lysed,
and the expression of the transfected pro-
teins and their association with Grb2 was de-
termined by immunoprecipitation and immu-
noblotting with specific antibodies.
(C) Enhancement of MAPKactivation by over-
expression of FRS2 or 4F-mutant. Human 293
cells were transfected with FRS2 (2 mg, lane 3) or 4F-mutant expression vectors (2 mg, lane 4), together with FGFR1 expression vector (1.5
mg, lanes 2±4) and an HA-tagged ERK1 expression vector (1.5 mg, lanes 1±4). After 48 hr, the cells were lysed, and the expression of transfected
protein was determined by immunoblotting with specific antibodies. The enzymatic activity of ERK1 was determined as described in Figure 4B.
(D) Quantitation of MAPK activation by FRS2 and 4F-mutant. ERK1 enzymatic activity was determined as described in Figure 4B. Background
activation was subtracted.
PTB domain of FRS2 may recognize a different amino Most growth factor receptors are able to recruit Grb2
acid sequence or may bind to an NPXYp sequence on by more than one mechanism. The EGF receptor, for
a different protein. Indeed, recent studies show that example, recruits Grb2/Sos both directly and indirectly
certain PTB domains bind with high affinity and specific- via tyrosine phosphorylation of Shc (Batzer et al., 1994).
ity to nonphosphorylated sequences in target proteins Insulin stimulation, on the other hand, leads to tyrosine
(Borg et al.,1996). We consider it likely that the myristyla- phosphorylation of Shc and IRS1, and both proteins
tion of FRS2, together with interactions mediated by the recruit Grb2/Sos (Skolniket al., 1993). This report reveals
PTB domain with FGFR or another unidentified mem- yet another mechanism for recruitment of Grb2/Sos in
brane protein, are responsible for stable anchoring in response to growth-factor stimulation. FGF stimulation
the cell membrane. This in turn is required for efficient leads to tyrosine phosphorylation of Shc and FRS2;
tyrosine phosphorylation of FRS2 in response to FGF- both tyrosine-phosphorylated proteins recruit Grb2/Sos
induced activation of the FGF receptor. complexes. The reason for the existence of multiple
It is interesting to compare the composition of the mechanisms for the recruitment of Grb2/Sos by receptor
amino-terminus of FRS2 with its analog in insulin-recep- tyrosine kinases and by tyrosine-phosphorylated dock-
tor signaling, IRS1. Both docking proteins are targeted ing proteins is currently unknown. Shc appears to be
to the cell surface, and membrane association is essen- a promiscuous target for tyrosine phosphorylation in
tial for efficient tyrosine phosphorylation by the FGF response to activation of a broad range of cell-surface
and insulin receptors, respectively. While IRS1 has a PH
receptors, including receptor tyrosine kinases, lympho-
domain followed by a PTB domain at its amino-terminus,
kine receptors, and G±protein coupled receptors, as well
however, FRS2 has a myristylation signal followed by a
as T±cell and B±cell antigen receptors. Since proteins
PTB domain. We suggest that the myristylation se-
such as FRS2 or IRS1 are tyrosine phosphorylated inquence of FRS2 and the PH domain of IRS1 fulfil a similar
response to a more restricted set of cell-surface stimuli,function: contributing (together with the PTB domain)
it is possible that these proteins mediate some of theto targeting of the proteins to the cell membrane for
more specific responses of FGF (and NGF) or insulin,interaction with the activated receptors. For example,
respectively.the myristylation signal of the Src family of nonreceptor
tyrosine kinases (Resh, 1994) has the same function as
a PH domain in the related nonreceptor tyrosine kinase,
Experimental ProceduresBtk (Vihinen et al., 1995). Furthermore, while rhodopsin
kinase is isoprenylated at its C-terminus (Inglese et al., Cell Lines
1992), the homologous Ser/Thr kinase of the b adrener- PC12 cells and L6 myoblasts (Mohammadi et al., 1992) expressing
gic receptor (bARK) has a C-terminal PH domain instead FGFR1 were previously described. HER14 cells are NIH-3T3 cells
that overexpress the human EGF-receptor (EGFR).(Pitcher et al., 1995).
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Antibodies and GST-Fusion Proteins Generation of PC12 Cells Stably Expressing FRS2
The cDNA for FRS2 was cloned into the pLXSN expression vector,Anti-Grb2 (N-SH3 domain), anti-Sos1, anti-phosphotyrosine (anti-
pY), anti-Shc, and anti-FGFR were previously described (Lowenstein and a high titer stock of virus was produced. Parental cells were
infected with a virus that combined wild-type FRS2 and the neomy-et al., 1992). Anti-EGFR and anti-GST antibodies were also pre-
viously described (Batzer et al., 1994). Anti-FRS2 antibodies were cin resistant gene and were selected for 1 week in medium supple-
mented with Geneticin (500 mg/ml). PC12 cells that express Ras(N17)generated against a GST-fusion protein containing the C-terminal
portion of the protein (aa 400±508). The anti-FRS2 antibodies were were infected with FRS2 expression virus that contains histidinol
dehydrogenase as a selection marker. Cells were selected with his-purified by protein A±Sepharose column and by affinity chromatog-
raphy. tidinol (800 mg/ml) for 2 weeks. Pools of selected cultures were used
in the studies. Expression of Ras(N17) was induced by overnight
treatment with 2 mM dexamethasone.Immunoprecipitation and Immunoblotting Analysis
Transfected cells expressing the various expression vectors were
starved overnight. Growth±factor stimulated cells were lysed and Microinjection of Anti-FRS2 Antibodies
subjected to immunoprecipitation and immunoblotting according to Rat embryo fibroblasts (REF-52) wereplated onto gridded coverslips
published procedures (Batzer et al., 1994; Mohammadi et al., 1996). (Bellco) and maintained in DMEM supplemented with 10% FCS. A
Precipitation with p13suc1 agarose (Calbiochem) was performed ac- solution containing affinity-purified anti-FRS2 antibodies (5 mg/ml)
cording to published procedures (Rabin et al., 1993). in 0.53 PBS was microinjected into the cytoplasm of all the cells
present in a chosen square of the coverslip (100±120 cells). One
hour after injection, cells were treated with 5 nM aFGF and 5 mg/Purification of FRS2 and Protein Sequencing
ml heparin, and BrdU was added to the culture medium at a concen-FRS2 was purified from NIH-3T3 cells that had been stimulated with
tration of 10 mM. After 26 hr, cells were fixed, permeabilized in acidaFGF and heparin. Cells were lysed, and the lysates were subjected
alcohol (ethanol:water:acetic acid, 90:5:5), and labeled with anti-to affinity chromatography with a Grb2±SH2 Affigel-10 column fol-
BrdU antibodies (Sigma) followed by staining with rhodamine-conju-lowed by affinity chromatography with anti-pY antibodies bound to
gated goat anti-mouse antibodies. Cells were viewed with an Axio-protein A±Sepharose. FRS2 was eluted from the antibody column
phot fluorescence microscope. DNA synthesis was determined bywith 100 mM phenylphosphate, and the sample was then applied
calculating the percentage of BrdU-positive cells as the number ofto an 8% SDS gel, transferred to a nitrocellulose filter, and visualized
BrdU-positive cells/total number of cells in the injected square 3by staining with Ponceau S. The band corresponding to FRS2 was
100. Control values were obtained by determining the percent ofexcised from the nitrocellulose filter. After digestion with porcine
BrdU-positive cells in an uninjected square.trypsin, the peptides were purified by reverse-phase HPLC and then
subjected to sequencing with an Applied Biosystems 494 using
standard reagents and programs from the manufacturer. Acknowledgments
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